Unknown

Dataset Information

0

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.


ABSTRACT: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

SUBMITTER: Uccellatore A 

PROVIDER: S-EPMC4575308 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7785877 | biostudies-literature
| S-EPMC5773971 | biostudies-literature
| S-EPMC4541559 | biostudies-literature
| S-EPMC7434822 | biostudies-literature
| S-EPMC7366314 | biostudies-literature
| S-EPMC5389657 | biostudies-literature
| S-EPMC5064617 | biostudies-literature
| S-EPMC6712219 | biostudies-literature
| S-EPMC4923410 | biostudies-literature
| S-EPMC1783418 | biostudies-literature